Supplementary Figure S4 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial

Key Points

• High immune expression correlates with improved progression-free survival in metastatic CRC patients receiving maintenance therapy.
• Mean values of epithelial tumor and stromal cells were analyzed to assess their impact on treatment outcomes in the trial.
• Analysis covered various treatment arms, underscoring the significance of the tumor immune microenvironment as a predictive factor.
• The findings imply biomarkers may enhance personalized treatment strategies for patients with RAS wt metastatic CRC.